CYP2D6 ultra-rapid metabolizer phenotype not associated with attempted suicide in a large sample of psychiatric inpatients

被引:0
|
作者
Stephens, Dustin B. [1 ]
de Leon, Jose [2 ]
机构
[1] Univ Kentucky, Coll Med, Dept Behav Sci, Lexington, KY 40536 USA
[2] Univ Kentucky, Coll Med, Dept Psychiat, Lexington, KY 40506 USA
关键词
CYP2D6; cytochrome P450; phenotype; self-harm; suicide; ultra-rapid; metabolizer; AMPLICHIP CYP450 TEST; CYP2C19; GENOTYPES; SEROTONIN; IMPACT; PHARMACOGENETICS; DEBRISOQUINE; BRAIN; PERSONALITY; ANTIDEPRESSANTS; POLYMORPHISM;
D O I
10.2217/pgs-2016-0086
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: Suicide accounts for over 800,000 deaths per year worldwide and is the tenth leading cause of mortality in USA. Several studies have investigated cytochrome P450 CYP2D6 ultra-rapid metabolizer (UM) phenotype in relation to suicidality, with mixed results. This study tested the hypothesis of increased suicide risk among CYP2D6 UMs. Patients & methods: Among the 4264 state psychiatric hospital inpatients included, 2435 (57%) reported a prior suicide attempt. Results: No association between UM status and attempted suicide was observed in bivariate (odds ratio: 0.87; 95% Cl: 0.531.25), multivariate (adjusted odds ratio: 0.89; 95% Cl: 0.55-1.46), or risk-stratified analyses. Conclusion: These results contrast with prior reports of increased suicidality among CYP2D6 UMs and highlight the pressing need to identify reliable screening methods to better address this persistent public health problem.
引用
收藏
页码:1295 / 1304
页数:10
相关论文
共 50 条
  • [1] Are you sure the patient is a CYP2D6 ultra-rapid metabolizer?
    Gregg, Keqin
    Guo, Wenjing
    Rhodes, Robert
    Simhadri, Ashrita
    Subramanya, Archana
    Samilpa, Paul
    Langley, Lyndsey
    Ames, Kyle
    McCarty, Matt
    PHARMACOGENOMICS, 2016, 17 (16) : 1749 - 1763
  • [2] On the impact of the CYP2D6 ultra-rapid metabolizer genotype on mirtazapine pharmacokinetics.
    Brockmöller, J
    Kirchheiner, J
    Henckel, H
    Meineke, I
    Roots, I
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P67 - P67
  • [3] Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets
    Kirchheiner, J
    Henckel, HB
    Franke, L
    Meineke, I
    Tzvetkov, M
    Uebelhack, R
    Roots, I
    Brockmöller, J
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (08): : 579 - 587
  • [4] Rapid detection of the ultraextensive metabolizer associated CYP2D6*35 polymorphism.
    Steimer, W
    Bachofer, J
    Leucht, S
    Müller, B
    CLINICAL CHEMISTRY, 2002, 48 (06) : A45 - A45
  • [5] Impact of the CYP2D6 ultra-rapid metabolizer genotype on cis- and trans-doxepin pharmacokinetics and serotonin concentration in platelets.
    Kirchheiner, JC
    Henckel, HB
    Franke, L
    Meineke, I
    Uebelhack, R
    Roots, I
    Brockmöller, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P26 - P26
  • [6] CYP2D6 METABOLIZER PHENOTYPE PREDICTS ARIPIPRAZOLE PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS
    Hiken, Eliah J.
    Poweleit, Ethan A.
    Keane, Corey
    Desta, Zeruesenay
    Strawn, Jeffrey R.
    Ramsey, Laura B.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2023, 62 (10): : S197 - S197
  • [7] A Meta-Analysis of CYP2D6 Metabolizer Phenotype and Metoprolol Pharmacokinetics
    Blake, C. M.
    Kharasch, E. D.
    Schwab, M.
    Nagele, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (03) : 394 - 399
  • [8] Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion
    Güzey, C
    Nordström, Å
    Spigset, O
    THERAPEUTIC DRUG MONITORING, 2002, 24 (03) : 436 - 437
  • [9] Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response
    Sowinski, KM
    Burlew, BS
    PHARMACOTHERAPY, 1997, 17 (06): : 1305 - 1310
  • [10] Impact of CYP2D6 metabolizer phenotype on the safety profile of paliperidone ER
    Dunbar, Fiona
    Chue, Pierre
    Fu, Dong-Jing
    Huang, Qiqing
    Franc, Monique-Andree
    Cohen, Nadine
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 83S - 83S